Literature DB >> 24678931

Using EFA and FIM rating scales could provide a more complete assessment of patients with acquired brain injury.

Peter W Stubbs1, Hanne Pallesen, Asger R Pedersen, Jørgen F Nielsen.   

Abstract

PURPOSE: In some hospitals, patients exhibit significant heterogeneity of function at admission and discharge. The current study aims to assess if concurrent usage of the Early Functional Assessment (EFA) and Functional Independence Measure (FIM) is warranted and practical in rehabilitation centers with diverse patient groups and outcomes.
METHODS: This retrospective study examined a data set of all patients with concurrent EFA and FIM scores admitted to a single rehabilitation center (4076 scores from 1251 patients). The patients had acquired brain injury of multiple etiologies and a range of severities.
RESULTS: The EFA scale was more able to characterize the function of lower functioning patients according to the FIM while the FIM scale was more able to characterize the function of higher functioning patients according to the EFA. This was highlighted by 21% of assessments with the lowest FIM score (18) having corresponding EFA scores of 22-76 and 27% of assessments with the highest EFA score (>90) having corresponding FIM scores of 38-126.
CONCLUSIONS: In rehabilitation centers with diverse patient groups and outcomes, the FIM and EFA scale could be used to characterize the heterogeneity of function in patients with acquired brain injury. The EFA/FIM scale could be used concurrently in certain patients providing a more complete view of patients throughout the rehabilitation process.

Entities:  

Keywords:  Brain injury; EFA; FIM; disability; functional independence measure

Mesh:

Year:  2014        PMID: 24678931     DOI: 10.3109/09638288.2014.904935

Source DB:  PubMed          Journal:  Disabil Rehabil        ISSN: 0963-8288            Impact factor:   3.033


  6 in total

1.  Early mobilisation by head-up tilt with stepping versus standard care after severe traumatic brain injury - Protocol for a randomised clinical feasibility trial.

Authors:  Christian Gunge Riberholt; Jane Lindschou; Christian Gluud; Jesper Mehlsen; Kirsten Møller
Journal:  Trials       Date:  2018-11-08       Impact factor: 2.279

2.  Validity of the Early Functional Ability scale (EFA) among critically ill patients undergoing early neurological rehabilitation.

Authors:  Melanie Boltzmann; Simone B Schmidt; Christoph Gutenbrunner; Joachim K Krauss; Günter U Höglinger; Christian Weimar; Jens D Rollnik
Journal:  BMC Neurol       Date:  2022-09-06       Impact factor: 2.903

3.  Reliability, validity, sensitivity and internal consistency of the ICF based Basic Mobility Scale for measuring the mobility of patients with musculoskeletal problems in the acute hospital setting: a prospective study.

Authors:  Karin Pieber; Malvina Herceg; Tatjana Paternostro-Sluga; Eleonore Pablik; Michael Quittan; Peter Nicolakis; Veronika Fialka-Moser; Richard Crevenna
Journal:  BMC Musculoskelet Disord       Date:  2015-08-05       Impact factor: 2.362

4.  Gastrointestinal transit time and heart rate variability in patients with mild acquired brain injury.

Authors:  Johannes Enevoldsen; Simon T Vistisen; Klaus Krogh; Jørgen F Nielsen; Karoline Knudsen; Per Borghammer; Henning Andersen
Journal:  PeerJ       Date:  2018-06-06       Impact factor: 2.984

5.  The effect of intensified nonverbal facilitation of swallowing on dysphagia after severe acquired brain injury: A randomised controlled pilot study.

Authors:  D Jakobsen; I Poulsen; C Schultheiss; C G Riberholt; D J Curtis; T H Petersen; R O Seidl
Journal:  NeuroRehabilitation       Date:  2019-12-18       Impact factor: 2.138

6.  Cohort profile: Design and implementation of the Danish Physiotherapy Research Database for patients receiving primary care with chronic disease.

Authors:  Erhard Næss-Schmidt; Nils-Bo de Vos Andersen; David Høyrup Christiansen; Jørgen Feldbæk Nielsen; Peter William Stubbs
Journal:  BMJ Open       Date:  2020-11-03       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.